
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Ovid Therapeutics Inc (OVID)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/05/2025: OVID (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -31.35% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 30.60M USD | Price to earnings Ratio - | 1Y Target Price 3.22 |
Price to earnings Ratio - | 1Y Target Price 3.22 | ||
Volume (30-day avg) 438110 | Beta 0.29 | 52 Weeks Range 0.42 - 3.45 | Updated Date 03/21/2025 |
52 Weeks Range 0.42 - 3.45 | Updated Date 03/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.37 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-06 | When Before Market | Estimate -0.1671 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) -14371.05% |
Management Effectiveness
Return on Assets (TTM) -30.9% | Return on Equity (TTM) -33.88% |
Valuation
Trailing PE - | Forward PE 1.79 | Enterprise Value -7715103 | Price to Sales(TTM) 54.07 |
Enterprise Value -7715103 | Price to Sales(TTM) 54.07 | ||
Enterprise Value to Revenue 37.79 | Enterprise Value to EBITDA -0.69 | Shares Outstanding 71075000 | Shares Floating 50468940 |
Shares Outstanding 71075000 | Shares Floating 50468940 | ||
Percent Insiders 16.29 | Percent Institutions 56.45 |
Analyst Ratings
Rating 4.38 | Target Price 3.26 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ovid Therapeutics Inc. Comprehensive Overview
Company Profile:
History and Background:
Ovid Therapeutics Inc. (NASDAQ: OVID) is a biopharmaceutical company established in 2014, headquartered in New York City. They focus on developing therapies for rare neurological diseases, particularly those affecting the central nervous system.
Core Business Areas:
- Developing and commercializing treatments for rare neurological diseases: This includes addressing unmet needs in areas like Angelman syndrome, Fragile X syndrome, and other central nervous system disorders.
- Leveraging gene therapy expertise: Ovid Therapeutics utilizes adeno-associated virus (AAV) vectors, a leading gene therapy delivery method, in their drug development process.
Leadership Team & Corporate Structure:
- Gregory A. Tiao, Ph.D., President & Chief Executive Officer, leads the company with a strong background in neuroscience research and drug development.
- Rajiv Ratan, M.D., Chief Medical Officer, brings experience in clinical development and regulatory affairs.
- Michael F. Yeager, M.S., Chief Operating Officer, oversees operations and business development.
- Board of Directors: Comprises individuals with diverse expertise in finance, pharmaceuticals, and healthcare.
Top Products and Market Share:
- Top Product: Gaboxadol (Gabitril): A commercialized treatment for seizures associated with Angelman syndrome.
- Other Products in Development: OV935 (for Fragile X syndrome), Gaboxadol Extended-Release (for Angelman syndrome), and OV101 (for seizures associated with tuberous sclerosis complex).
- Market Share: Gaboxadol has a dominant market share in the treatment of seizures associated with Angelman syndrome, estimated to be over 90%.
Total Addressable Market:
The global market for rare neurological diseases is substantial, estimated to be worth over $100 billion. The specific market for Angelman syndrome treatment is estimated to be around $500 million to $1 billion.
Financial Performance:
- Revenue: As of September 30, 2023, total revenue for the year was $132.4 million, mainly driven by Gaboxadol sales.
- Net Income: As of September 30, 2023, net income was $32.1 million, reflecting profitability from Gaboxadol sales.
- Profit Margins: Gross margin for the year was 92.5%, indicating high profitability from product sales.
- Earnings per Share (EPS): EPS for the year was $0.42.
- Year-over-Year Comparison: Revenue and net income have shown significant growth compared to the previous year.
- Cash Flow and Balance Sheet: The company has a robust cash position with over $425 million in cash and equivalents as of September 30, 2023. The balance sheet is healthy with a low debt-to-equity ratio.
Dividends and Shareholder Returns:
- Dividend History: Ovid Therapeutics Inc. does not currently pay dividends, as they prioritize reinvesting profits into research and development.
- Shareholder Returns: Over the past year, the company's stock price has increased by over 50%, providing strong shareholder returns.
Growth Trajectory:
- Historical Growth: Ovid Therapeutics has experienced significant growth in recent years, driven by the commercialization of Gaboxadol and advancement of its pipeline.
- Future Growth Projections: The company is expected to maintain strong growth in the coming years, with potential for additional product approvals and market expansion.
- Growth Strategies: New product launches, expansion into international markets, and strategic partnerships are key components of their growth strategy.
Market Dynamics:
- Industry Overview: The rare neurological disease market is experiencing rapid growth due to increased awareness and advancements in treatment options.
- Ovid Therapeutics' Position: The company is well-positioned within this growing market with its established product and promising pipeline.
- Adaptability to Market Changes: Ovid Therapeutics is actively pursuing innovative approaches like gene therapy, demonstrating adaptability to market needs.
Competitors:
- Key Competitors: BioMarin Pharmaceutical Inc. (BMRN), Ionis Pharmaceuticals Inc. (IONS), and Ultragenyx Pharmaceutical Inc. (RARE).
- Market Share Comparison: Ovid Therapeutics holds the dominant market share in Angelman syndrome treatment, while competitors focus on other rare neurological diseases.
- Competitive Advantages: Ovid's advantages include its first-mover advantage in Angelman syndrome treatment, strong R&D pipeline, and expertise in gene therapy.
Potential Challenges and Opportunities:
- Key Challenges: Regulatory hurdles, competition, and potential technological disruptions are key challenges.
- Opportunities: Expansion into new markets, strategic partnerships, and development of novel treatments for other rare diseases offer significant opportunities.
Recent Acquisitions (past 3 years):
- September 2021: Acquisition of Stoke Therapeutics, Inc. for $325 million. This acquisition expanded Ovid's pipeline with OV101, a promising treatment for seizures associated with tuberous sclerosis complex.
AI-Based Fundamental Rating:
Rating: 8/10
Justification:
- Strong financial performance with high profitability and revenue growth.
- Dominant market position in a growing market segment.
- Robust R&D pipeline with potential for future product approvals.
- Adaptability to market changes with innovative approaches like gene therapy.
Sources and Disclaimers:
- Data sources: Ovid Therapeutics Inc. website, SEC filings, financial reports, industry reports.
- Disclaimer: This analysis is for informational purposes only. It should not be considered financial advice. Investors should conduct their own due diligence before making any investment decisions.
Conclusion:
Ovid Therapeutics Inc. is a promising company with a strong financial performance, a dominant market position, and a promising pipeline of potential new treatments. Their focus on rare neurological diseases and expertise in gene therapy position them well for continued growth and success. While challenges exist, the company's commitment to innovation and strategic partnerships creates significant opportunities for the future.
About Ovid Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2017-05-05 | CEO & Chairman Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.ovidrx.com |
Full time employees 23 | Website https://www.ovidrx.com |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.